10
views
0
recommends
+1 Recommend
3 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Trayectorias del dolor en sujetos con afección post-covid-19: estudio prospectivo y transversal con evaluación presencial Translated title: Pain paths among post-covid-19 condition subjects: a prospective cross-sectional study with in-person evaluation

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          RESUMEN Antecedentes: El dolor crónico de nueva aparición se considera que forma parte de la condición o afección post-COVID-19. Sin embargo, los datos detallados existentes sobre el fenotipo clínico, las trayectorias y las principales características asociadas siguen siendo escasos. Describimos las distintas evoluciones temporales del dolor post-COVID-19 y sus rasgos epidemiológicos y fenotípicos. Métodos: Estudio prospectivo y transversal de pacientes con afección post-COVID-19 (es decir, con síntomas persistentes relacionados con la COVID-19 durante 30 días desde la primera prueba positiva de laboratorio) cuyo diagnóstico de COVID-19 estuviera basado en la RT-PCR de un frotis oral/nasofaríngeo o una serología. Se sometieron a evaluaciones presenciales mediante una entrevista estructurada, cuestionarios de dolor y calidad de vida y una exploración física exhaustiva. El dolor crónico (DC) y el dolor neuropático (DN) probablemente se definieron conforme a los criterios IASP. Resultados: El presente estudio incluyó 226 individuos, 177 (78,3 %) de los cuales se presentaron pasados más de 3 meses desde el primer síntoma de COVID-19. Tenían dolor de nueva aparición 170 (75,2 %) de los participantes y dolor crónico 116 (68,2 %). El curso crónico se asociaba a hospitalización por COVID-19, fatiga de nueva aparición, menor rendimiento cognitivo, déficits motores y sensitivos térmicos, alteraciones del ánimo y el sueño, y niveles generalmente inferiores de calidad de vida. El DN probable afectaba a solo el 7,6 % de los pacientes con dolor de nueva aparición y se asociaba a cronificación del dolor, fatiga de nueva aparición, déficits motores y de sensación térmica, alodinia mecánica y tasas menores de vacunación frente al SARS-CoV-2. Referían DC previo 86 (38,1 %) individuos, y este había empeorado tras la infección en 66 (76,7 %) de ellos, lo que se asociaba a hipotensión ortostática. Conclusiones: Los fenómenos dolorosos post-COVID siguen diferentes trayectorias que se asocian a rasgos clínicos y epidemiológicos específicos, y posiblemente a distintos mecanismos de base y diferentes implicaciones pronósticas y terapéuticas. Significado: El dolor relacionado con la COVID-19 sigue normalmente un curso crónico y no es neuropático. Los posibles cursos y fenotipos se asocian a rasgos clínicos y epidemiológicos distintos. Esto sugiere que los mecanismos de base difieren, lo que podría tener implicaciones pronósticas y terapéuticas importantes.

          Translated abstract

          ABSTRACT Background: New-onset chronic pain has been acknowledged as part of the post-COVID-19 condition. However, available fine-grained data about its clinical phenotype, trajectories and main associated characteristics remain scarce. We described the distinct temporal evolutions of post-COVID-19 pain and their epidemiological and phenotypical features. Methods: A prospective cross-sectional study enrolled post-COVID-19 condition patients (i.e. who had persisting COVID-19-related symptoms over 30 days since their first positive laboratory test), whose COVID-19 diagnosis had been supported by RT-PCR of oral/nasopharyngeal swab or serology. They underwent in-person evaluations with a structured interview, pain and quality-of-life-related questionnaires and thorough physical examination. Chronic pain (CP) and probable neuropathic pain (NP) were defined according to IASP criteria. Results: The present study included 226 individuals, 177 (78.3 %) of whom presented over 3 months since their first COVID-19 symptom. New-onset pain occurred in 170 (75.2 %) participants and was chronic in 116 (68.2 %). A chronic course was associated with COVID-19-related hospitalization, new-onset fatigue, lower cognitive performance, motor and thermal sensory deficits, mood and sleep impairments and overall lower quality-of-life levels. Probable NP occurred in only 7.6 % new-onset pain patients, and was associated with pain chronification, new-onset fatigue, motor and thermal sensory deficits, mechanical allodynia and lower rates of SARS-CoV-2 vaccination. Previous CP was reported by 86 (38.1 %) individuals and had aggravated after the infection in 66 (76.7 %) of them, which was associated with orthostatic hypotension. Conclusions: Post-COVID pain phenomena follow different paths, which are associated with specific clinical and epidemiological features, and possibly distinct underlying mechanisms, prognostic and therapeutic implications. Significance: COVID-19-related pain usually follows a chronic course and is non-neuropathic. Its possible courses and phenotypes are associated with distinct clinical and epidemiological features. This suggests differing underlying mechnisms, which may have significant prognostic and therapeutic implications.

          Related collections

          Most cited references54

          • Record: found
          • Abstract: found
          • Article: not found

          Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

          Research electronic data capture (REDCap) is a novel workflow methodology and software solution designed for rapid development and deployment of electronic data capture tools to support clinical and translational research. We present: (1) a brief description of the REDCap metadata-driven software toolset; (2) detail concerning the capture and use of study-related metadata from scientific research teams; (3) measures of impact for REDCap; (4) details concerning a consortium network of domestic and international institutions collaborating on the project; and (5) strengths and limitations of the REDCap system. REDCap is currently supporting 286 translational research projects in a growing collaborative network including 27 active partner institutions.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The REDCap consortium: Building an international community of software platform partners

            The Research Electronic Data Capture (REDCap) data management platform was developed in 2004 to address an institutional need at Vanderbilt University, then shared with a limited number of adopting sites beginning in 2006. Given bi-directional benefit in early sharing experiments, we created a broader consortium sharing and support model for any academic, non-profit, or government partner wishing to adopt the software. Our sharing framework and consortium-based support model have evolved over time along with the size of the consortium (currently more than 3200 REDCap partners across 128 countries). While the "REDCap Consortium" model represents only one example of how to build and disseminate a software platform, lessons learned from our approach may assist other research institutions seeking to build and disseminate innovative technologies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A clinical case definition of post-COVID-19 condition by a Delphi consensus

              People with COVID-19 might have sustained postinfection sequelae. Known by a variety of names, including long COVID or long-haul COVID, and listed in the ICD-10 classification as post-COVID-19 condition since September, 2020, this occurrence is variable in its expression and its impact. The absence of a globally standardised and agreed-upon definition hampers progress in characterisation of its epidemiology and the development of candidate treatments. In a WHO-led Delphi process, we engaged with an international panel of 265 patients, clinicians, researchers, and WHO staff to develop a consensus definition for this condition. 14 domains and 45 items were evaluated in two rounds of the Delphi process to create a final consensus definition for adults: post-COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset, with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis. Common symptoms include, but are not limited to, fatigue, shortness of breath, and cognitive dysfunction, and generally have an impact on everyday functioning. Symptoms might be new onset following initial recovery from an acute COVID-19 episode or persist from the initial illness. Symptoms might also fluctuate or relapse over time. A separate definition might be applicable for children. Although the consensus definition is likely to change as knowledge increases, this common framework provides a foundation for ongoing and future studies of epidemiology, risk factors, clinical characteristics, and therapy.
                Bookmark

                Author and article information

                Journal
                dolor
                Revista de la Sociedad Española del Dolor
                Rev. Soc. Esp. Dolor
                Inspira Network Group, S.L (Madrid, Madrid, Spain )
                1134-8046
                April 2023
                : 30
                : 2
                : 131-145
                Affiliations
                [6] São Paulo orgnameUniversidad de São Paulo orgdiv1Hospital Universitario orgdiv2Centro de Investigación Clínica y Epidemiológica. Centro Interdisciplinario de Neuromodulación Aplicada Brasil
                [4] São Paulo orgnameUniversidad de São Paulo orgdiv1Facultad de Medicina orgdiv2Laboratorio de Patología Clínica. Departamento de Psiquiatría. Instituto de Psiquiatría Brasil
                [3] São Paulo orgnameUniversidad de São Paulo orgdiv1Facultad de Medicina orgdiv2Servicio de Neuromodulación Interdisciplinario. Departamento de Psiquiatría. Instituto de Psiquiatría Brasil
                [7] Aalborg orgnameUniversidad de Aalborg orgdiv1Facultad de Medicina orgdiv2Centro de Neuroplasticidad y Dolor (CNAP). Departamento de Ciencia y Tecnología de la Salud Dinamarca
                [2] São Paulo orgnameInstituto Oncológico del Estado de São Paulo orgdiv1Centro de Tratamiento del Dolor Brasil
                [5] São Paulo orgnameUniversidad de São Paulo orgdiv1Facultad de Medicina orgdiv2Laboratorio de Neurociencia. Departamento de Psiquiatría. Instituto de Psiquiatría. Instituto Nacional de Biomarcadores en Psiquiatría Brasil
                [1] São Paulo orgnameUniversidad de São Paulo orgdiv1Departamento de Neurología orgdiv2LIM-62. Centro de Dolor Brasil
                Article
                S1134-80462023000200010 S1134-8046(23)03000200010
                10.1002/ejp.2094
                36799447
                b81c4748-625c-44a7-8cd3-a99d59a5eaba

                This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

                History
                : 12 February 2023
                : 11 December 2022
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 54, Pages: 15
                Product

                SciELO Spain

                Categories
                Artículo de la revista EJP

                Comments

                Comment on this article